Chen JY, et al. - Considering the preclinical studies suggesting an antifibrotic role for tricyclic antidepressants (TCA), researchers investigated the impact of TCA use on fibrosis progression and development of hepatocellular carcinoma (HCC) among hepatitis C virus (HCV)-infected persons using the Electronically Retrieved Cohort of HCV Infected Veterans. Findings revealed decreased fibrosis progression and lower risk of developing cirrhosis in association with TCAs use, supporting the beneficial effects of TCAs on progression of liver fibrosis in patients with chronic HCV infection.